Pliant Therapeutics Inc. (PLRX) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Pliant Therapeutics Inc. (NASDAQ: PLRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.84 (-2.29% 1D, market cap $53.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PLRX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TLPH (Talphera Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $53.5M) and XLO (Xilio Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $52.8M). Among the 5-stock peer group, PLRX leads on earnings multiple (N/A) while PLRX leads on capital efficiency (-35.0% ROIC).
Per PLRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001746473), Pliant Therapeutics Inc. generated $437.8M in revenue (-31.5% YoY), $149.3M in net income, and -$128.7M in free cash flow against $225.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 35.3 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While PLRX currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.04) and Max Pain ($0.88) forces dealer call-delta covering toward $1.91.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Pliant Therapeutics Inc. (PLRX) dropped -2.29% to $0.84, trading at 2% of its 52-week range ($0.83 – $1.82). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Pliant Therapeutics Inc. (PLRX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Pliant Therapeutics Inc. (PLRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Pliant Therapeutics Inc. (PLRX) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering Pliant Therapeutics Inc. (PLRX) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Pliant Therapeutics Inc. (PLRX) market action, institutional positioning, and fundamental catalysts.
Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nas
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-10109
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Dir
Appointments bring global oncology drug development experience and deepen Board’s operational and regulatory expertise SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLR
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months Data highlighted in oral presentation at AACR’s Clinical Trials Mini Symposium
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -31.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PLRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PLRX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Pliant Therapeutics Inc. (PLRX) ranks #641 by composite RQD confidence (34/100, grade E) and #735 by equity capitalization ($53.2M). Within this direct 5-issuer industry benchmark cohort, PLRX leads on earnings valuation at N/A trailing P/E, while PLRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. HYFT currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with PLRX at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PLRX
ACTIVE
Pliant Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -2.29% | $53.2M | Benchmark Subject |
| TLPH Talphera Inc. | D- | 36/100 | — | — | -35.0% | -1.94% | $53.5M | /tlph-vs-plrx → |
| XLO Xilio Therapeutics Inc. | E | 25/100 | — | — | -35.0% | -0.50% | $52.8M | /xlo-vs-plrx → |
| HRTX Heron Therapeutics Inc. | E | 34/100 | — | 73.3% | -35.0% | +6.27% | $52.7M | /hrtx-vs-plrx → |
| HYFT MindWalk Holdings Corp. | D | 45/100 | — | — | — | -2.65% | $53.8M | /hyft-vs-plrx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pliant Therapeutics Inc. (PLRX) reported GAAP revenue of $437.8M (-31.5% vs. FY2024 revenue of $639.4M , and +27611.7% cumulative change since FY2023) , GAAP net income of $149.3M, operating cash flow of -$128.3M, and free cash flow of -$128.7M (+19.2% YoY). On the balance sheet, PLRX closed FY2025 with $225.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $437.8M | $149.3M | -$128.3M | -$128.7M | $225.2M | — |
| FY2024 (FY) | 2024-12-31 | $639.4M | $210.3M | -$155.5M | -$159.4M | $396.9M | — |
| FY2023 (FY) | 2023-12-31 | $1.6M | $161.3M | -$116.4M | -$116.4M | — | — |
As of 2026-11-03, Pliant Therapeutics Inc. (NASDAQ: PLRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.84 (-2.29% 1D, market cap $53.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PLRX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TLPH (Talphera Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $53.5M) and XLO (Xilio Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $52.8M). Among the 5-stock peer group, PLRX leads on earnings multiple (N/A) while PLRX leads on capital efficiency (-35.0% ROIC).
Per PLRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001746473), Pliant Therapeutics Inc. generated $437.8M in revenue (-31.5% YoY), $149.3M in net income, and -$128.7M in free cash flow against $225.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
PLRX last traded at $0.84 (-2.29% on volume of 385,692 shares), positioning the stock -19.23% below its 50-day simple moving average ($1.04) and -27.59% below its 200-day simple moving average ($1.16). Across its 52-week range of $0.83 to $1.82, PLRX sits at the 1.0% percentile with a 14-day RSI of 35.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($1.00 to $0.94).
Pliant Therapeutics Inc. (PLRX) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.84 (-2.29% 1D, market capitalization $53.2M).
Pliant Therapeutics Inc. (PLRX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile does not describe its products, customers, or revenue model. The financials report revenue of — for FY 2025 and FY 2024 and $1.6M for FY 2023 ().
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Pliant Therapeutics Inc. (PLRX) reported $437.8M in annual revenue (up from $639.4M in FY2024, -31.5% YoY) and $149.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.6M revenue, $161.3M net income) through FY2025, PLRX scaled operating cash flow to -$128.3M and free cash flow to -$128.7M, backed by $225.2M in total assets against $0 in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PLRX carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Pliant Therapeutics Inc. (PLRX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Pliant Therapeutics Inc. (PLRX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Pliant Therapeutics Inc. (PLRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Pliant Therapeutics Inc. (PLRX) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering Pliant Therapeutics Inc. (PLRX) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Pliant Therapeutics Inc. (PLRX) market action, institutional positioning, and fundamental catalysts.
Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nas
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-10109
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Dir
Long PLRX at $0.86 targeting $1.08. Institutional accumulation and options positioning earn the stock 12 of 20 on the whale-flow pillar, the strongest of its five scores.. Institutional whale score is 4/20 and the risk/reward vs. the $0.83 52-week low is skewed heavily in favor of bulls.
@FadeTheHype Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
I respect the product at Pliant Therapeutics Inc., but the stock at $0.86 is a different story. ROIC of -35% and 0% FCF yield, with free cash outflows of $116M–$159M against $45.4M of cash, point to a cash-consumptive business with runway and dilution risk.. FCF yield is 0.0% and RQD sits at 34/100 (E) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: